<DOC>
	<DOC>NCT01718145</DOC>
	<brief_summary>The purpose of this study is to assess the anti-viral activity of BMS-790052 and BMS-650032 combination therapy in Japanese subject. The purpose of this study is to compare the anti-viral activity of the co-administration of Asunaprevir (ASV) and Daclatasvir (DCV) to Telaprevir (TVR) included therapy in Japanese Hepatitis C virus (HCV) subjects</brief_summary>
	<brief_title>A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects</brief_title>
	<detailed_description>Intervention Model: Parallel in the Naive cohort and Single group in the Relapser cohort</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Chronic HCV1b infected patient HCV Ribonucleic acid (RNA) &gt; 100,000 IU/mL at screening Ages 20 to 70 years (for the Naive cohort), ages 20 to 75 years (for the Relapser cohort) Treatment naive subjects to Interferon (IFN) based therapy Subjects who had undetectable HCV RNA at end of treatment with prior exposure to an IFNcontaining regimen, but HCV RNA detectable within 24 weeks of treatment followup Patients who have; Hepatocellular carcinoma Coinfection with Hepatitis B virus (HBV) or Human immunodeficiency virus (HIV) Severe or uncontrollable complication</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>